Danaher Corporation $DHR Shares Purchased by Dash Acquisitions Inc.

Key Points

• Dash Acquisitions Inc. increased its stake in Danaher Corporation (NYSE:DHR) by 2.6%, owning a total of 81,185 shares worth approximately $16 million as of the latest SEC filing.
• Danaher recently reported a quarterly earnings per share (EPS) of $1.80, surpassing analyst expectations of $1.64, along with a year-over-year revenue growth of 3.4%.
• The company declared a quarterly dividend of $0.32 per share, scheduled for payment on October 31, representing an annualized yield of 0.6%.

Dash Acquisitions Inc. raised its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 2.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 81,185 shares of the conglomerate's stock after acquiring an additional 2,070 shares during the period. Danaher makes up approximately 3.4% of Dash Acquisitions Inc.'s investment portfolio, making the stock its 11th largest position. Dash Acquisitions Inc.'s holdings in Danaher were worth $16,066,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. MGO One Seven LLC increased its stake in Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after acquiring an additional 20,813 shares during the last quarter. Chicago Capital LLC grew its stake in shares of Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate's stock worth $2,634,000 after acquiring an additional 1,391 shares in the last quarter. UniSuper Management Pty Ltd grew its stake in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock worth $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. acquired a new position in Danaher during the 1st quarter worth approximately $539,000. Finally, Horizon Financial Services LLC grew its stake in shares of Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock opened at $206.19 on Wednesday. The firm has a market capitalization of $147.64 billion, a price-to-earnings ratio of 43.87, a price-to-earnings-growth ratio of 2.92 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a 50 day moving average price of $200.96 and a 200 day moving average price of $197.13. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is 27.23%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DHR. Weiss Ratings reissued a "hold (c-)" rating on shares of Danaher in a research report on Wednesday, October 8th. Redburn Partners set a $220.00 price objective on shares of Danaher in a research report on Wednesday, October 8th. Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Barclays reiterated an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Evercore ISI lifted their price target on Danaher from $226.00 to $245.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 7th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $244.60.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.20% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.